1. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials
- Author
-
Clarita C. Maaño, Chandra F Meghrajani, and Charlene Marie U Ang-Tiu
- Subjects
medicine.medical_specialty ,Erythema ,Chemistry, Pharmaceutical ,Calcineurin Inhibitors ,Treatment outcome ,Administration, Cutaneous ,Placebo ,Tacrolimus ,law.invention ,Pimecrolimus ,Maintenance therapy ,Randomized controlled trial ,law ,Seborrheic dermatitis ,medicine ,Animals ,Humans ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,skin and connective tissue diseases ,Randomized Controlled Trials as Topic ,integumentary system ,business.industry ,General Medicine ,medicine.disease ,Dermatology ,Dermatitis, Seborrheic ,Calcineurin ,Treatment Outcome ,Dermatologic Agents ,medicine.symptom ,business ,medicine.drug - Abstract
Seborrheic dermatitis is a common, chronic, relapsing inflammatory skin disorder that manifests as erythema, scaling and pruritus in sebum gland-rich areas of the skin. The objective of this article is to evaluate the clinical efficacy of pimecrolimus 1% cream in the treatment of seborrheic dermatitis compared with corticosteroids, antimycotics, placebo or no intervention. Pimecrolimus 1% cream appears to be a well-tolerated and effective treatment for seborrheic dermatitis. It has comparable efficacy, in terms of decreasing severity of erythema, scaling and pruritus, to the standard treatments: topical corticosteroids and antimycotics. However, future studies with more standardized measures of treatment outcome are recommended. More studies may also be conducted to further evaluate pimecrolimus 1% cream as a long-term maintenance therapy for seborrheic dermatitis.
- Published
- 2012
- Full Text
- View/download PDF